Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Greater Cannabis CoGCAN 30 OCF Yield % is -19.06 as of Aug. 11, 2026. GuruFocus rates GCAN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Greater Cannabis Co ranks worse than 91.14% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Greater Cannabis Co OCF Yield % Related Terms
Greater Cannabis Co OCF Yield % Historical Data
* Premium members only.
The historical data trend for Greater Cannabis Co's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Greater Cannabis Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greater Cannabis Co OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Greater Cannabis Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Greater Cannabis Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greater Cannabis Co (GCAN) has a OCF Yield % of -19.06 as of Aug. 11, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Greater Cannabis Co and its competitors. According to the industry distribution chart, Greater Cannabis Co ranks #916 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 91.1%.
Is Greater Cannabis Co's OCF Yield % too high?
Greater Cannabis Co's current OCF Yield % is -19.06. Based on the distribution chart, Greater Cannabis Co ranks #916 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Greater Cannabis Co has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Greater Cannabis Co's OCF Yield % compare to STEK and KAYS?
According to the Drug Manufacturers industry distribution chart, Greater Cannabis Co ranks #916 out of 1005 companies for OCF Yield %. This places Greater Cannabis Co in the lower half of its industry. The industry median OCF Yield % is 3.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.45, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Greater Cannabis Co and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greater Cannabis Co's current OCF Yield % is -19.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greater Cannabis Co stock overvalued right now?
Greater Cannabis Co (GCAN) has a current OCF Yield % of -19.06. The current OCF Yield % is -19.06. Greater Cannabis Co's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Greater Cannabis Co (GCAN), the current OCF Yield % is -19.06 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greater Cannabis Co Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a pharma-grade therapeutic that reduces disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications. The company is focused on developing new formulations around cannabinoid therapeutics.
30GF Score
Get the complete analysis for GCAN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GCAN has been successfully added to your 
